ONTAK
information and resources from the National Cancer Institute
NCI Thesaurus | ONTAK
(Other name for: denileukin diftitox)NCI Thesaurus | ONTAK
(Other name for: denileukin diftitox)
Denileukin diftitox
Accel. Approv. (clinical benefit not established) treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor
Seragen, Inc Feb 05 1999
|
|
|
|
news articles
FDA MedWatch - Ontak (denileukin Diftitox) Associated with Loss OF ... Mar 16, 2006
PharmaLive.com (press release), Ligand Pharmaceuticals and FDA notified healthcare professionals of changes to the WARNINGS section of the prescribing information for Ontak, indicated for the ...
Ligand Announces Preliminary Unaudited Financial Results for 2005 Mar 17, 2006
PharmaLive.com (press release), ...to prior year, although we note that fourth quarter AVINZA (primarily due to our decision to eliminate some low margin Medicaid business) and ONTAK(R) product ...
Sanofi Will Be Losing Sleep over Potential Wave of Ambien Claims Mar 16, 2006
Newsinferno.com, ...have caused chronic cases of the very same condition the drugs were designed to treat; and (3) loss of color vision caused by ONTAK (denileukin diftitox), a ...
Phase II Study Demonstrates that ONTAK(R) Benefits Patients with ... Dec 14, 2005
Business Wire (press release), Ligand Pharmaceuticals Incorporated (Pink Sheets:LGND) cancer drug ONTAK(R) (denileukin diftitox) benefits patients with relapsed/refractory T-cell and B-cell ...
Phase II Study Demonstrates that ONTAK Benefits Patients with ... Dec 15, 2005
PharmaLive.com (press release), SAN DIEGO--(BUSINESS WIRE)--Dec 14, 2005--Ligand Pharmaceuticals Incorporated (Pink Sheets:LGND) cancer drug ONTAK(R) (denileukin diftitox) benefits patients ...
Ligand Announces Final Results and Filing of Forms 10Q For First ... Dec 9, 2005
Genetic Engineering News, The 5% increase in the third quarter sales of ONTAK(R) and flat trend for the nine months ended September 30, 2005 compared to the same periods in 2004 ...
Ligand Pharmaceuticals presents new data Dec 15, 2005
San Diego Daily Transcript (subscription), ...(Pink: LGND.PK, News) shows that the cancer drug Ontak benefits patients with relapsed/refractory T-cell and B-cell non-Hodgkin's lymphoma. ...
Ligand Announces Preliminary Revenue Estimates For Third Quarter ... Nov 18, 2005
Business Wire (press release), ...the second quarter 2005 with $70.1 million in cash, cash equivalents, short-term investments and restricted investments after completing the ONTAK(R) royalty ...
Cancer Vaccine Research Gets a Boost Nov 25, 2005
Forbes But by using an already-approved lymphoma cancer drug, called Ontak, to eliminate T-regs in kidney cancer patients before administering a treatment vaccine ...
|
|
